2-噻唑甲胺二盐酸盐 | 53332-78-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-噻唑甲胺二盐酸盐
• 中文别名: 2-噻唑甲胺双盐酸盐；2-(氨乙基)噻唑双盐酸盐；2-氨基甲基噻唑(双盐酸盐)；2-(氨乙基)三唑双盐酸盐
• 英文名称: 2-(Aminomethyl)thiazole Dihydrochloride
• 英文别名: 1,3-thiazol-2-ylmethanamine;dihydrochloride
• CAS: 53332-78-8
• 化学式: C4H8Cl2N2S
• 分子量: 187.09
• InChiKey: SXOAJLQMTFZXKM-UHFFFAOYSA-N

物化性质

• 沸点：
  36℃/0.5mm

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.2
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

文献信息

• [EN] BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR<br/>[FR] COMPOSÉS BICYCLIQUES AYANT UNE ACTIVITÉ SUR LE RÉCEPTEUR CXCR4
  申请人：ALLERGAN INC

  公开号：WO2009143058A1

  公开（公告）日：2009-11-26

  A compound represented by the structural formula (I): Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

  由结构式(I)表示的化合物：还公开了相关的治疗方法、组合物和药物。
• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。
• [EN] COMPOUNDS FOR IMPROVING MRNA SPLICING<br/>[FR] COMPOSÉS POUR AMÉLIORER L'ÉPISSAGE DE L'ARNM
  申请人：GEN HOSPITAL CORP

  公开号：WO2016115434A1

  公开（公告）日：2016-07-21

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

  本文提供了一些有助于改善细胞内mRNA剪接的化合物。本文提供的示例化合物有助于改善包含至少一个以核苷酸序列CAA结尾的外显子的基因的mRNA剪接。还提供了制备这些化合物的方法以及治疗中枢神经系统疾病的方法。
• [EN] ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR<br/>[FR] ANTAGONISTES DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：ADORX THERAPEUTICS LTD

  公开号：WO2021224636A1

  公开（公告）日：2021-11-11

  The present invention relates to compounds of formula I shown below: wherein R0, R1, R2, R3 and A are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

  本发明涉及如下所示的公式I的化合物：其中R0、R1、R2、R3和A分别如申请中所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，并将其用于治疗涉及腺苷A2a受体活性的疾病或症状，例如癌症。
• Tyrosine kinase inhibitors
  申请人：Dinsmore Christopher J.

  公开号：US20090012076A1

  公开（公告）日：2009-01-08

  The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

  本发明涉及对细胞增殖性疾病有用的5H-苯并[4,5]环庚[1,2-b]吡啶衍生物，用于治疗与MET活性相关的疾病，并用于抑制受体酪氨酸激酶MET。该发明还涉及包含这些化合物的组合物，以及利用它们来治疗哺乳动物癌症的方法。